NCT02690948View on ClinicalTrials.gov

Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

February 1, 2016

Primary Completion Date

November 30, 2017

Study Completion Date

August 29, 2018

Conditions
Skin Basal Cell Carcinoma
Interventions
BIOLOGICAL

Pembrolizumab

Given IV

DRUG

Vismodegib

Given PO

Trial Locations (1)

94304

Stanford University School of Medicine, Palo Alto

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

Anne Chang

OTHER

NCT02690948 - Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer | Biotech Hunter | Biotech Hunter